
New CAR-T Cell Therapy Shows Hope for Refractory CD30+ Lymphoma Patients
May 3, 2025
Researchers at Sant Pau Research Institute, in partnership with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed a groundbreaking CAR-T cell therapy—HSP-CAR30—targeting the CD30 protein. This therapy has shown promising results in a Phase I clinical